Roche Investor Relations ASCO Planner 2015

Transcription

1 Roche Investor Relations ASCO Planner 2015 Saturday, May 30 Session Title: Developmental Therapeutics Immunotherapy Poster Board: #341 Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-pdl1 antibody MPDL3280A. (Abstract #3015) Scott N. Gettinger, MD Session Title: Breast Cancer HER2/ER Poster Board: #74 Total pathologic complete response (tpcr) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (Abstract #585) Christian Jackisch, MD F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations Tel Fax

2 Session Title: Melanoma/Skin Cancers Location: E354b Time: 1:15 PM - 4:15 PM Chair and/or Co-Chairs: Axel Hauschild, MD, and Sekwon Jang, MD 3:15 PM - 3:27 PM Update of progression-free survival (PFS) and correlative biomarker analysis from cobrim: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (Abstract #9006) James M. G. Larkin, MD, PhD Session Title: Health Services Research and Quality of Care Location: S102 Time: 1:15 PM - 4:15 PM Chair and/or Co-Chairs: Helen M. Parsons, PhD, MPH, and Ann H. Partridge, MD, MPH 2:27 PM - 2:39 PM Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG (Abstract #6504) Deborah Schrag, MD, MPH Session Title: Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Location: E Hall D1 Time: 3:00 PM - 6:00 PM Chair and/or Co-Chairs: Scott N. Gettinger, MD, and Charles M. Rudin, MD, PhD 3:00 PM - 3:12 PM Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. (Abstract #7500) Gerard Zalcman, MD, PhD

3 Sunday, May 31 Session Title: Lung Cancer Non-Small Cell Metastatic Location: N Hall B1 Time: 8:00 AM - 11:00 AM Chair and/or Co-Chairs: Luis G. Paz-Ares, MD, PhD, and Nithya Ramnath, MD 10:24 AM - 10:36 AM Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). (Abstract #8008) Sai-Hong Ignatius Ou Session Title: Lymphoma and Plasma Cell Disorders Poster Board: #352 Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC- 0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin s Lymphoma (NHL). (Abstract #8535) Sven De Vos, MD, PhD Poster Board: #394 Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8576) Shaji Kumar, MD Poster Board: #398 Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8580) Cyrille Touzeau, MD Session Title: Plenary Session Including the Science of Oncology Award and Lecture Session Type: Plenary Session Location: N Hall B1 Time: 1:00 PM - 4:00 PM Chair and/or Co-Chairs: Peter P. Yu, MD, FACP, FASCO, and Alan P. Venook, MD

4 Session Title: Immunotherapy in Lung Cancer: A Paradigm Shift Session Type: Clinical Science Symposium Location: E Hall D1 Time: 4:30 PM - 6:00 PM Chair and/or Co-Chairs: Nathan A. Pennell, MD, PhD, and Geoffrey R. Oxnard, MD 4:42 PM - 4:54 PM Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract #8010) Alexander I. Spira, MD, PhD Monday, June 1 Session Title: Breast Cancer HER2/ER Location: N Hall B1 Time: 8:00 AM - 11:00 AM Chair and/or Co-Chairs: Priya Rastogi, MD, and Tufia C. Haddad, MD 8:12 AM - 8:24 AM Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB (Alliance). (Abstract #501) Maura N. Dickler, MD 9:48 AM - 10:00 AM Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). (Abstract #505) Luca Gianni, MD 10:00 AM - 10:12 AM Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial. (Abstract #506) Nadia Harbeck, MD, PhD 10:12 AM - 10:24 AM Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (Abstract #507) Paul Anthony Ellis

5 Session Title: Gynecologic Cancer Location: E354b Time: 8:00 AM - 11:00 AM Chair and/or Co-Chairs: Rebecca S. Kristeleit, MD, PhD, and John K. Chan, MD 9:12 AM - 9:24 AM Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (Abstract #5504) Christian Kurzeder, MD Session Title: Lung Cancer Non-Small Cell Metastatic Poster Board: #341 A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-smallcell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (Abstract #8019) Leena Gandhi, MD, PhD Poster Board: #350 Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-pdl1) in PD-L1 selected patients with non-small cell lung cancer (NSCLC). (Abstract #8028) David R. Spigel, MD Poster Board: #351 Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-pdl1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (Abstract #8029) Leora Horn, MD, MSc Poster Board: #352 Safety and efficacy of MPDL3280A (anti-pdl1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #8030) Stephen V. Liu, MD

6 Session Title: Lymphoma Location: E450 Time: 9:45 AM - 12:45 PM Chair and/or Co-Chairs: Owen A. O'Connor, MD, PhD, and Grzegorz S. Nowakowski, MD 10:09 AM - 10:21 AM GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non- Hodgkin lymphoma. (Abstract #LBA8502) Laurie Helen Sehn, MDCM, MPH Session Title: Genitourinary (Nonprostate) Cancer Location: E Arie Crown Theater Time: 9:45 AM - 12:45 PM Chair and/or Co-Chairs: Guru Sonpavde, MD, and Ana M. Molina, MD 9:57 AM - 10:09 AM A phase Ia study of MPDL3280A (anti-pdl1): Updated response and survival data in urothelial bladder cancer (UBC). (Abstract #4501) Daniel Peter Petrylak, MD Session Title: Melanoma/Skin Cancers Time: 1:15 PM - 4:45 PM Poster Board: #263 Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. (Abstract #9020) Anna C. Pavlick, DO Poster Board: #267 Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. (Abstract #9024) Reinhard Dummer, MD